SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Body weight reduction and pharmacological therapy for diabetes such as glucagon-like peptide-1 (GLP-1) agonists and sodium glucose cotransporter 2 (SGLT2) inhibitors ameliorate pathological findings of NAFLD [19].